Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Diabetes: Update Bulletin [August 2014]

Product Code:
596200300
Release Date:
August 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Diabetes: Toujeo, Eli Lilly/Boehringer Ingelheim’s Abasria, Novo Nordisk’s Xultophy/IDegLira, peglispro

Highlights from this event update bulletin

  • Toujeo’s higher concentration seen as a welcome arrival
  • Less nocturnal hypoglycaemia with Toujeo not seen as significant advantage
  • Toujeo’s success will depend on pricing and marketing
  • Abasria viewed with optimism in EU, less so in US
  • Basal insulin peglispro’s hepatopreferential mechanism of action garners interest
  • Basal insulin peglispro’s safety concerns may hinder uptake
  • Novo Nordisk’s Xultophy/IDegLira seen as effective therapy after oral failure

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved